Tumor Biology

, Volume 37, Issue 2, pp 2177–2181 | Cite as

Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer

  • Teresa Granato
  • Lucia Manganaro
  • Luca Petri
  • Maria Grazia Porpora
  • Valentina Viggiani
  • Antonio Angeloni
  • Emanuela Anastasi
Original Article

Abstract

The objective of this study was to evaluate the correlation between 25-OH vitamin D and ovarian cancer as a diagnostic marker or recurrence disease marker. We studied the following: (1) 61 women without gynecologic diseases, (2) 45 women affected by benign ovarian disease, (3) 46 women with recent diagnosis of ovarian cancer, (4) 26 follow-up women with recurrent ovarian cancer, and (5) 32 follow-up women with stable ovarian cancer. The 25-OH vitamin D was quantified with LUMIPULSE® G 25-OH vitamin D on LUMIPULSE® G 1200 (Fujirebio, Japan). As a threshold value, identified by ROC curve analysis, 20.2 ng/mL (sensitivity 73.3 %, specificity 84 %) was chosen corresponding to the limit between sufficient and insufficient 25-OH vitamin D according to the WHO. Low 25-OH vitamin D levels were observed in 26 % of women without gynecologic diseases, in 80 % of women with recent diagnosis of ovarian cancer and in 24 % women affected by benign ovarian diseases (p < 0.001). The follow-up study showed an insufficient level of 25-OH vitamin D in 73 % women with recurrent ovarian cancer and in 47 % women with stable ovarian cancer (p < 0.0003). This study showed that patients with ovarian cancer are often insufficient in 25-OH vitamin D compared to women with benign ovarian diseases. The women with recurrent ovarian cancer presented more often low levels compared to women with stable ovarian cancer. This study suggests that 25-OH vitamin D, due to its antiproliferative properties, can be a good marker for ovarian cancer also.

Keywords

25-OH vitamin D Biomarker Epithelial ovarian cancer Follow-up 

Notes

Acknowledgments

This study is founded by the University of Rome Sapienza. The authors are thankful to Giuseppina Gennarini, Barbara Colaprisca, and Silvestra Tudini for their excellent technical assistance.

Conflicts of interest

None

References

  1. 1.
    Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, ESMO Guidelines Working Group, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:24–32.CrossRefGoogle Scholar
  2. 2.
    Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer. 2015;5. doi: 10.1038/bjc.2015.22.
  3. 3.
    di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, et al. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med. 2015;41C:1–115.CrossRefGoogle Scholar
  4. 4.
    Xie J, Poole EM, Terry KL, Fung TT, Rosner BA, Willett WC, et al. A prospective cohort study of dietary indices and incidence of epithelial ovarian cancer. J Ovarian Res. 2014;7(1):112–4.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang G, Zhang Q, Xu N, Xu K, Wang J, He W, et al. Associations between two polymorphisms (FokI and BsmI) of vitamin D receptor gene and type 1 diabetes mellitus in Asian population: a meta analysis. PLoS One. 2014;9(3):e89325.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Attar R, Gasparri ML, Donato VD, Yaylim I, Halim TA, Zaman F, et al. Ovarian cancer: interplay of vitamin D signaling and miRNA action. Asian Pac J Cancer Prev. 2014;15(8):3359–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Watanabe R, Inoue D. Current topics on vitamin D. Anti-cancer effects of vitamin D. Clin Calcium. 2015;25(3):373–80.PubMedGoogle Scholar
  8. 8.
    Wranicz J, Szostak-Węgierek D. Health outcomes of vitamin D. Part II. Role in prevention of diseases. Rocz Panstw Zakl Hig. 2014;65(4):273–9.PubMedGoogle Scholar
  9. 9.
    Gandini S, Gnagnarella P, Serrano D, Pasquali E, Raimondi S. Vitamin D receptor polymorphisms and cancer. Adv Exp Med Biol. 2014;810:69–105.PubMedGoogle Scholar
  10. 10.
    Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T,et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;2. doi: 10.1002/cncr.29320.
  11. 11.
    Nemazannikova N, Antonas K, Dass CR. Vitamin D: metabolism, molecular mechanisms, and mutations to malignancies. Mol Carcinog. 2014;53(6):421–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Li S, Xu H, Li SC, Qi XQ, Sun WJ. Vitamin D receptor rs2228570 polymorphism and susceptibly to ovarian cancer: a meta-analysis. Tumour Biol. 2014;35(2):1319–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4. doi: 10.1016/j.CrossRefPubMedGoogle Scholar
  14. 14.
    Bonfrer JM, Duffy MJ, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Aebi S, Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis; treatment and follow-up. Ann Oncol. 2009;20(Supp4):iv21–3.Google Scholar
  16. 16.
    Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30:2481–7.PubMedGoogle Scholar
  18. 18.
    Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biol. 2012;33:1291–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Falzarano R, Viggiani V, Michienzi S, Longo F, Tudini S, Frati L, et al. Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers. Tumour Biol. 2013;34(5):3093–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:23–30.CrossRefGoogle Scholar
  23. 23.
    Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lynch HT, Drescher K, Knezetic J, Lanspa S. Genetics biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review. Curr Treat Options Oncol. 2001;15:429–42.CrossRefGoogle Scholar
  25. 25.
    Guideline No. 62RCOG/BSGE Joint Guideline Royal College guidelines 2011. Management of suspected ovarian masses in premenopausal women. Green-top.Google Scholar
  26. 26.
    Mutch D, Denny L, Quinn M. FIGO Committee on Gynecologic Oncology. Hereditary gynecologic cancers. Int J Gynaecol Obstet. 2014;124:189–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Granato T, Porpora MG, Longo F, Angeloni A, Lucia Manganaro L, Anastasi E. He4 in the differential diagnosis of ovarian masses. Clin Chim Acta. 2015;446:147–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Walentowicz-Sadłecka M, Sadłecki P, Walentowicz P, Grabiec M. The role of vitamin D in the carcinogenesis of breast and ovarian cancer. Ginekol Pol. 2013;84(4):305–8.PubMedGoogle Scholar
  29. 29.
    Irazoqui AP, Boland RL, Buitrago CG. Actions of 1,25(OH)2-vitamin D3 on the cellular cycle depend on VDR and p38 MAPK in skeletal muscle cells. J Mol Endocrinol. 2014;53(3):331–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol. 2009;193:461–70.CrossRefPubMedGoogle Scholar
  31. 31.
    Irving AA, Plum LA, Blaser WJ, Ford MR, Weng C, Clipson L, et al. Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer. J Nutr. 2015;145(2):291–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Teresa Granato
    • 1
  • Lucia Manganaro
    • 2
  • Luca Petri
    • 3
  • Maria Grazia Porpora
    • 4
  • Valentina Viggiani
    • 3
  • Antonio Angeloni
    • 3
  • Emanuela Anastasi
    • 3
  1. 1.CNR-IBPM, National Research CouncilRomeItaly
  2. 2.Department of Radiological, Oncological, and Pathological Sciences“Sapienza” University of RomeRomeItaly
  3. 3.Department of Molecular Medicine“Sapienza” University of RomeRomeItaly
  4. 4.Department of Gynecology, Obstetrics and Urology“Sapienza” University of RomeRomeItaly

Personalised recommendations